[Sign in] [Register]   

EIAab logo

Index > News Center > News list.
Enter your KeyWord (Ex. ELISA Kit, Cuticular Active Peptide Factor, etc)
Search content in infomation.

ELISA Applied training

Posted by star on 2018-08-01 20:13:58


    On the morning of July 31, 2018, Wuhan EIAAB Science co., LTD held a successful training about the application of ELISA kit.

    Zhang Ting who is a member of the technology department mainly introduced the following three aspects to the company personnel: 1. Basic components of the ELISA Kit; 2. Application of ELISA Kit in biomedical science; 3. Application of ELISA in other fields. It mainly consists of three parts of ELISA test, as well as basic knowledge such as different classification according to the analysis principle. Examples are given to explain the applications of ELISA kit, which greatly strengthens the understanding of sales personnel and further clarifies the work content.

    When Zhang Ting explained the related methods of the ELISA kit, everyone listened carefully and also actively participated in the communication. At the end of the presentation, the company personnel asked their own questions and Zhang Ting fluently answered all the questions. And we believe that the spirit and attitude of keeping improving in work with every personnel will certainly make the company go further!

An AIDS vaccine passed an early human trial

Posted by star on 2018-07-31 19:22:11


    Animal and early human trials have shown that a new AIDS vaccine is safe and can induce an immune response, and then they will conduct efficacy trials in a wider population.

    Researchers at Harvard University reported Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) in a new issue of the British Lancet that the vaccine is a "mosaic vaccine" that splicing the genes of different HIV strains to target a wider range of HIV. The strain induces an immune response. This is the fifth AIDS vaccine to enter the second phase of clinical efficacy trials in 35 years. Only one of the four vaccines had a protective effect. The AIDS vaccine called RV144 reduced the risk of infection by 31%.

    In the latest trial, researchers recruited 393 healthy adults from countries such as South Africa, Thailand, and the United States, and volunteers were randomized to a “mosaic vaccine” or placebo. The results showed that the vaccine successfully induced an antiviral immune response and the subject was well tolerated.

    Experiments conducted with 72 macaques showed that this "mosaic vaccine" protected 48 of them from being infected with human monkey chimeric immunodeficiency virus (SHIV). The human monkey chimeric immunodeficiency virus is similar to HIV and can infect monkeys.

    Currently, researchers have initiated Phase II clinical efficacy trials in Southern Africa. A total of 2,600 high-risk women with HIV infection are participating, and trial results are expected in 2021 or 2022.

Spider silk proteins help the vaccine activate immune cells

Posted by star on 2018-07-05 23:08:12

Recently, Swiss and German researchers have devised a new program for the manufacture of vaccines. The use of spider silk proteins to encapsulate antigens can safely transport antigens to T cells in lymphoid tissues, greatly enhancing the effectiveness of vaccines in stimulating immune responses. Researchers said the technology helps design a stable, easy-to-use, storage-resistant vaccine.

For cancer and some important infectious diseases, small pieces of protein, antigenic peptides, need to be delivered to T cells so that they can learn to recognize related pathogens and produce immunity. If injected directly, antigenic peptides will decompose before reaching the "destination". How to safely and efficiently transport antigenic peptides is a difficult point in the development of vaccines.

The researchers published the paper Engineered hybrid spider silk particles as delivery system for peptide vaccines in the International Journal of Biomaterials. They combined antigenic peptides with a spider silk protein to create nano-sized particles that successfully delivered antigen peptides and activated T cells without the need for a vaccine adjuvant, and showed no evidence of immunotoxicity.

The vaccine particles are very stable, easy to manufacture and can be adjusted as needed. In addition, the vaccine particles have good heat resistance and can be stored in an environment exceeding 100 degrees Celsius for several hours.

Researchers first artificially synthesize human prions

Posted by star on 2018-07-04 19:21:56

The famous mad cow disease is caused by prions. Such prion diseases not only affect animals, but also seriously endanger human health. American researchers recently published Artificial strain of human prions created in vitro in the journal Nature-Communication. They first synthesized human prions, which are important for understanding the structure and replication of the virus and developing therapeutic methods.

The essence of prions is protein. If the protein in the central nervous system of humans and some animals is folded incorrectly, it will form a prion with infectious properties. They are constantly combined with adjacent normal proteins in the brain, causing cavernous cavities in the brain, leading to symptoms such as degeneration of the brain and dementia and eventually death.

Previously, researchers were able to extract several prions from rodents, but mouse experiments have shown that these prions are not contagious to humans, and their structure and replication are different from human prions.

Researchers have used genetic technology to engineer E. coli to produce human prions, eventually resulting in a new, highly destructive human prion. The ability to synthesize human prions in test tubes will allow us to gain a deeper understanding of its structure and replication, which is critical for the development of inhibitors.

The researchers also discovered a cofactor involved in prion diseases: ganglioside GM1. It plays a regulatory role in inte......

Researchers Determine Pancreatic Cancer Tissue Consumption Mechanism

Posted by star on 2018-07-03 19:13:48

On June 21, Nature published Altered exocrine function can drive adipose wasting in early pancreatic cancer. This study shows that changes in exocrine function of the pancreas may be the cause of adipose tissue and skeletal muscle depletion in patients with pancreatic cancer.

Changes in cellular metabolism are symptoms exhibited by various cancers. Peripheral tissue depletion is particularly closely related to pancreatic cancer. This metabolic syndrome lowers the quality of life and is also thought to reduce the survival rate of cancer patients. There are many causes of organizational consumption, but it has been difficult to determine the exact underlying mechanism.

Researchers found that the loss of adipose tissue and skeletal muscle occurred early in the development of the disease through the mouse model of pancreatic cancer, and that it caused the growth of pancreatic tumors rather than tumor growth in other parts of the body. They also stated that a decline in the exocrine function of the pancreas will promote the loss of adipose tissue. Supplementation with pancreatic enzymes can reduce peripheral tissue depletion, but it will not increase the survival rate of mice.

Of the 782 pancreatic cancer patients, 65% had symptoms of skeletal muscle depletion at the time of diagnosis. However, adipose tissue and skeletal muscle depletion were not associated with reduced patient survival. Therefore, peripheral tissue depletion in the early stages of pancreatic cancer may be an early warning s......

Page 4 of 85
Hot Genes
ALCAM ACE KSR2 ASPRO C19orf80 Gdf5 Trap1a Atf2
Top Searches
Ubiquitin ELISA Ubiquitin-protein ligase metalloproteinase Asprosin TRAP1A Tumor necrosis vitamin d
Why choose EIAAB
Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
Further Information
About us Protein center Bank account Distributors Terms & Conditions Career

Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab